



Premalignant/malignant histology in excised choledochal cyst specimens from children. Experience and literature review

Tadaharu Okazaki¹ · Koki Nikai^{1,2} · Hiroyuki Koga² · Go Miyano¹ · Takanori Ochi² · Geoffrey J. Lane² · Yuki Fukumura³ · Atsuyuki Yamataka²

Accepted: 25 October 2023

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023

Abstract

Background Dysplasia, carcinoma in situ, and other malignant transformation or premalignant/malignant histopathology (PMMH) seem uncommon in pediatric choledochal cyst (CC). A literature review and the authors' experience are presented.

Methods All reports about PMMH in CC patients 15 years old or younger published in English and all cases of PMMH in specimens excised from CC patients 15 years old or younger by the authors were reviewed.

Results Of 20 published reports, PMMH was adenocarcinoma ($n=4$), sarcoma ($n=4$), and dysplasia ($n=12$). Treatment for malignancies was primary pancreaticoduodenectomy (PD; $n=2$) or cyst excision/hepaticojejunostomy (Ex/HJ; $n=6$). Outcomes at the time of writing for malignancies: 2 deaths, 4 survivors after follow-up of 2 years, and 2 lost to follow-up. No dysplasia case has undergone malignant transformation. The authors have experienced 7 cases of PMMH; adenocarcinoma in situ (AIS; $n=1$) and dysplasia ($n=6$).

Conclusions The present study identified the youngest cases of AIS and dysplasia from specimens excised when they were 3 years old and 4 months old, respectively. Both are published for the first time as evidence that PMMH can complicate CC in young patients. Long-term protocolized postoperative follow-up is mandatory when PMMH is diagnosed in pediatric CC.

Keywords Choledochal cyst · Pancreaticobiliary maljunction (PBMJ) · Malignancy · Cholangiocarcinoma · Dysplasia · Pediatric

Introduction

Irwin and Morison [1] and Ferraris et al. [2] reported an association between choledochal cyst (CC) and malignancy, premalignant/malignant histopathology (PMMH) defined as dysplasia, carcinoma in situ, and other malignant transformation. PMMH has been identified in excised specimens from adult CC patients [3–5], but specific data for pediatric CC patients are lacking. In the present study, PMMH cases published in the English language literature and the

authors' experience were reviewed and two cases presented to improve knowledge about PMMH in pediatric CC.

Methods

Systematic searches of English-language articles were conducted using the PubMed database developed and maintained by the National Center for Biotechnology Information at the US National Library of Medicine (NLM), located at the National Institutes of Health (NIH). PubMed facilitates searching across several NLM literature resources such as MEDLINE, PubMed Central, and Bookshelf. Keywords used were choledochal cyst, pancreaticobiliary maljunction (PBMJ), malignancy, cholangiocarcinoma, dysplasia, and pediatric. Pediatric was defined as up to and including 15 years old at the time of cyst excision (Ex) and hepaticojejunostomy biliary tract reconstruction, usually hepaticojejunostomy (HJ) at the authors' institutes. All searches were performed on August 27 and 28 in 2023.

✉ Tadaharu Okazaki
okazakit@juntendo.ac.jp

¹ Department of Pediatric Surgery, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu-shi, Chiba, Japan

² Department of Pediatric General and Urogenital Surgery, Juntendo University Graduate School of Medicine, Tokyo, Japan

³ Department of Human Pathology, Juntendo University Graduate School of Medicine, Tokyo, Japan

The authors also reviewed all pediatric CC patients who had histopathologic evidence for PMMT in excised CC and gallbladder specimens between 2001 and 2023. For histopathologic examination, hematoxylin–eosin (H&E) staining and in recent cases, S-100protein, maspin, and IMP3 immunohistochemical staining to distinguish between dysplasia and benign epithelium in the biliary tree were employed.

Results

Literature review

Table 1 summarizes published cases. There were 20 reports of PMMH in pediatric CC patients aged up to and including 15 years old; 8 cases of malignancy (4 adenocarcinoma and 4 sarcoma) and 12 cases of dysplasia. All PMMH were identified in CC specimens. For treatment of the 8 published malignancy cases, primary pancreaticoduodenectomy was performed in 2 cases because adenocarcinoma was confirmed on intraoperative histopathologic diagnosis (published case 4) and a metastatic lesion was confirmed preoperatively (published case 5). For the other 6 published malignant cases, Ex and choledochojejunostomy or HJ were performed because a definitive histopathologic diagnosis of malignancy was not made intraoperatively. Six published malignant cases (cases 1 to 6) had adjuvant chemotherapy. Details for cases 7 and 8 are unknown. At the time of writing, 2 of the published malignant cases were dead, 4 were alive but had only been followed up for less than 2 years, cases 7 and 8 were lost to follow-up.

Published cases 9–20 all had dysplasia in excised CC specimens diagnosed after definitive Ex/HE. At the time of

writing, no malignant transformation has been reported in any dysplasia case after follow-up ranging from 1 to 3 years.

The authors' experience

At the time of writing, 7 cases of PMMH have been identified in 169 CC cases (4.1%) treated by the authors at their institutes between 2001 and 2023 (Table 2). One case was adenocarcinoma in situ (AIS) and 6 were dysplasia. Histopathologic diagnosis of PMMH was made after Ex/HJ in all 7 cases. PMMT was identified in excised CC ($n=4$), excised gall bladder (GB; $n=2$) and both (CC + GB; $n=1$). Immunohistochemistry using S-100P, maspin, and IMP3 was performed on tissue from the 4 dysplasia cases; excised CC PMMH lesions were positive for maspin and IMP3 and negative for S-100P ($n=3$; author cases 5, 6, and 7). All PMMH cases were diagnosed after Ex/HJ from histopathologic assessment of excised specimens. Despite being diagnosed with PMMH, none have received adjuvant chemotherapy and at the time of writing, all 7 PMMH cases were alive and well. None of the authors' cases have been published. The AIS case (authors' case 1) and one dysplasia case (authors' case 6) are presented.

Authors' case 1

A 3-year-2-month-old boy was admitted for suspected pancreatitis. At presentation, serum amylase (AMY) (133 IU/L) and lipase (LIP) (529 IU/L) were elevated, but serum direct bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and γ -glutamyl transpeptidase (GGTP) were all within reference ranges. Magnetic resonance cholangiopancreatography (MRCP) identified PBMJ and cystic CC without dilated intrahepatic bile ducts. There were no

Table 1 Summary of published cases

Published cases [reference no]	Published	Sex	Age at surgery	Surgery performed	Pathology	PMMH site	Outcome*	Follow-up period*
1 [6]	1976	F	5 yr	Ex + CJ	Sarcoma	CC	Alive	1 yr
2 [7]	1990	F	12 yr	Ex + HJ	Adenocarcinoma	CC	Dead	2 yr
3 [8]	1992	F	6 yr	Ex + HJ	Sarcoma	CC	Alive	N/A
4 [9]	2006	M	11 yr	PD	Adenocarcinoma	CC	Alive	1 yr 1 mo
5 [10]	2008	F	15 yr	PD	Adenocarcinoma	CC	Dead	1 yr 2 mo
6 [11]	2009	M	3 yr 11 mo	Ex + HJ	Adenocarcinoma	CC	Alive	1 yr
7 [12]	2015	N/A	3 yr	Ex + HJ	Rhabdomyosarcoma	CC	N/A	N/A
8 [12]	2015	N/A	4 yr	Ex + HJ	Rhabdomyosarcoma	CC	N/A	N/A
9–20 [13]	2003	N/A	N/A	Ex + HJ	Dysplasia	CC	N/A	N/A

CC choledochal cyst, CJ choledochojejunostomy, Ex cyst excision, GB gallbladder, HJ hepaticojejunostomy

N/A not available, PD pancreaticoduodenectomy, PMMH premalignant/malignant histology

*at the time of publication

yr years, mo months

Table 2 Summary of authors' cases

Patients	Sex	Age at surgery	Surgery performed	Pathology	Immunohistochemistry results	PMMH site	Outcome*	Follow-up period*
Case 1	M	3 yr 2 mo	Ex + HJ	Adenocarcinoma in Situ	N/A	CC	Alive	12 yr 8 mo
Case 2	F	2 yr 10 mo	Ex + HJ	Dysplasia	N/A	CC, GB	Alive	18 yr 9 mo
Case 3	F	11 mo	Ex + HJ	Dysplasia	N/A	GB	Alive	14 yr 6 mo
Case 4	F	1 yr 4 mo	Ex + HJ	Dysplasia	S-100P (-), Maspin (-), IMP3 (-)	GB	Alive	4 yr 8 mo
Case 5	M	12 yr 7 mo	Ex + HJ	Dysplasia	S-100P (-), Maspin (+), IMP3 (+)	CC	Alive	3 yr 6 mo
Case 6	F	4 mo	Ex + HJ	Dysplasia	S-100P (-), Maspin (+), IMP3 (+)	CC	Alive	1 yr 8 mo
Case 7	F	1 yr 3 mo	Ex + HJ	Dysplasia	S-100P (-), Maspin (+), IMP3 (+)	CC	Alive	1 yr 3 mo

CC choledochal cyst, Ex cyst excision, GB gallbladder, HJ hepaticojejunostomy
 N/A not available, PD pancreaticoduodenectomy, PMMH premalignant/malignant histology
 *at the time of writing
 yr years, mo months


other remarkable findings on MRCP or ultrasonography (US). Laparoscopic Ex with HJ was performed. Histopathology of the excised CC identified an increase in the number of glandular lumens associated with carcinogenesis, as well as back-to-back glands. In this lesion, cells showed anisokaryosis, irregular nuclei, and cloudy mucus within the cytoplasm, typical findings of AIS (Fig. 1). Proximal and distal margins of the excised CC were negative for evidence of malignancy. Although adjuvant chemotherapy was not

performed, follow-up has been more intensive because of the diagnosis of AIS. MRCP and US have continued to be unremarkable for almost 13 years; he is currently almost 16 years old and well.

Authors' case 6

A 7-day-old girl was admitted for suspected CC on routine abdominal echography. Biochemistry identified elevated

Fig. 1 Histopathology: authors' case 1. **A** Open arrowheads show an increase in the number of glandular lumens associated with carcinogenesis, as well as back-to-back glands. **B** Cells show anisokaryosis, irregular nuclei (red arrows), and cloudy mucus within the cytoplasm (open arrowheads). **C** Cells show no anisokaryosis. **D** Irregular nuclei and mucus within the cytoplasm are not seen



serum direct bilirubin (18.2 mg/dL), AST (50 IU/L), and GGTP (272 IU/L). AMY and LIP were within reference ranges. She underwent tube drainage of the CC on day 10 of life, followed by Ex with HJ at 4 months old. Histopathology showed micropapillary architecture, and loss of cellular polarity, anisokaryosis, and hyperchromasia on H&E staining. Immunohistochemical examination revealed diffuse, intermediate to strong cytoplasmic staining for IMP3, and diffuse, strong, and combined nuclear/cytoplasmic staining patterns for maspin (Fig. 2), indicating dysplasia of the mucosa of CC. She has been well postoperatively and is currently 20 months old.

Discussion

Although a few PMMH cases complicating pediatric CC have been reported, the authors have expanded the data base for PMMH in pediatric CC from 21 to 27 by presenting the youngest case of AIS diagnosed in an excised specimen from a 3-year-2-month-old boy followed-up for more than 10 years, and the youngest case of dysplasia diagnosed in an excised specimen from a 4-month-old girl.

CC is known as being one of the high-risk factors for the development of carcinoma of the biliary tract ranging from 2.5% to 30% for all age groups [13–15] because of its association with PBMJ. However, reports of pediatric cases are rare. It has been considered that reflux of pancreatic secretions into bile causes inflammation, repeated cycles of damage and healing of the biliary epithelium, and can promote malignant transformation [16]. In fact,

disrupted mucosa of excised CC was observed next to the lesion of AIS in the authors' case 1 (Fig. 3). Patients with CC develop malignancies at a younger age compared with cholangiocarcinoma patients (median: 49.5 years versus 65 years, respectively) [3, 17]. Moreover, Gao R, et al. reported that age, recurrent attacks of biliary pancreatitis, symptom duration, cyst diameter, and history of biliary surgery are individual risk factors for premalignant lesions in younger aged CC patients [12]. However, 2 malignant cases (published case 6 [11] and authors' case 1) and 5 dysplasia cases (authors' cases 2, 3, 4, 6, and 7) were all less than 5 years old when specimens were excised. As a result, it would be prudent for an entire excised specimen to be examined thoroughly by skilled pathologists with immunochemistry such as S-100P, maspin, and IMP3 as well as more traditional staining techniques to distinguish between dysplasia and benign epithelium in the biliary tree





Fig. 3 Damaged CC mucosa in authors' case 1. The dotted circle indicates partially damaged CC mucosa between sites of adenocarcinoma in situ (dashed rectangles). Note fibrin deposition (arrowheads) next to the AIS lesion

Fig. 2 Histopathology: authors' case 4. **A, B** Epithelial cells harbor enlarged and hyperchromatic nuclei with thickened nuclear membrane. **C** Cells show diffuse, intermediate, to strong cytoplasmic staining for IMP3. **D** Cells show diffuse, strong, and combined nuclear/cytoplasmic staining patterns for maspin



precisely [18, 19]. The present study should encourage pediatric surgeons to have a high index of suspicion for carcinogenesis in younger CC patients and foster acceptance that CC has an oncologic aspect that has not been a routine focus of management or follow-up to date.

Although Ex and HE are generally accepted as standard surgical intervention for CC, published cases 4 and 5 had pancreaticoduodenectomy and both cases can be considered as unique examples of malignancies complicating CC; in fact, in published case 4, a slightly elevated lesion was present and biopsied. The general consensus can be summarized by Saikura et al. [11] who advocated early radical surgery combined with thorough intraoperative histopathology examination once CC was diagnosed. Minimally invasive surgery using laparoscopy with 4 K imaging [20] as well as intraoperative endoscopy performed routinely by the authors, even during laparoscopic Ex and HE to examine the common channel, CC, and intrahepatic bile duct [21] for debris and calculi have improved surgery for CC. Intraoperative endoscopy is excellent for careful mucosal examination and irrigation during Ex.

This study has clinical impact by providing evidence for the existence PMMH in pediatric CC. To the best of the authors' knowledge, there is only 1 report specifically about PMMH in pediatric CC, Gao, et al. [13] who reported 12/210 CC cases (5.7%) with dysplasia and no reports investigating the incidence of PMMH in excised specimens from adults with CC. By comparing Gao's data with the authors' experience where PMMH was identified in 7/169 CC cases (4.1%), it would appear that the incidence of PMMH in pediatric CC is of the order of 5%, which is not low compared with reported incidences ranging from 2.5% to 30% for all age groups [13–15]. This result is noteworthy because it was unexpectedly high and surgeons should be aware of PMMH in young children less than 3 years old with CC. The importance of thorough histopathologic examination and meticulous protocolized follow-up are mandatory for managing pediatric CC patients thoroughly and safely.

Author contributions T.O. and A.Y. wrote the main manuscript text. All authors performed clinical data collection. Y.F. performed histopathologic examination. G.L. made English corrections. All authors reviewed the manuscript.

Data availability The datasets generated and/analyzed during current study are available from the corresponding author on reasonable request.

Declarations

Competing interests The authors declare no competing interests.

References

1. Irwin ST, Morison JE (1944) Congenital cyst of the common bile-duct containing stones and undergoing cancerous change. *Br J Surg* 32:319
2. Ferraris LV, Navarro A, Malbran JE (1944) Dilatation congenital del hepatocodedoco y adenocarcinoma. *Bol Soc Cir Cordaba* 5:21
3. Ten Hove A, de Meijer VE, Hulscher JBF, de Kleine RHL (2018) Meta-analysis of risk of developing malignancy in congenital choledochal malformation. *Br J Surg* 105:482–490. <https://doi.org/10.1002/bjs.10798>
4. Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P (2016) Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of cholangiocarcinoma (ENS-CCA). *Nat Rev Gastroenterol Hepatol* 13:261–280. <https://doi.org/10.1038/nrgastro.2016.51>
5. Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA (2020) Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. *J Hepatol* 72:95–103. <https://doi.org/10.1016/j.jhep.2019.09.007>
6. Tsuchiya R, Harada N, Ito T, Furukawa M, Yoshihiro I, Kusano T, Uchimura M (1976) Malignant tumors in choledochal cysts. *Ann Surg* 186:22–28
7. Iwai N, Deguchi E, Yanagihara J, Iwai M, Matsuo H, Todo S, Imashuku S (1990) Cancer arising in a choledochal cyst in a 12-year-old girl. *J Pediatr Surg* 25:1261–1263
8. Patil KK, Omojola MF, Khurana P, Iyengar JK (1992) Embryonal rhabdomyosarcoma within a choledochal cyst. *Can Assoc Radiol J* 43:145–148
9. Tanaka S, Kubota M, Yagi M, Okuyama A, Ohtaki M, Yamazaki S, Hirayama Y, Kurosaki I, Hatakeyama K (2006) An 11-year-old male patient demonstrating cholangiocarcinoma associated with congenital biliary dilatation. *J Pediatr Surg* 41:e15-19
10. Nakamura H, Katayose Y, Rikiyama T, Onogawa T, Yamamoto K, Yoshida H, Hayashi H, Ohtsuka H, Hayashi Y, Egawa S (2008) Advanced bile duct carcinoma in a 15-year-old patient with pancreaticobiliary maljunction and congenital biliary cystic disease. *J Hepatobiliary Pancreat Surg* 15:554–559
11. Saikura N, Naito S, Inuma Y, Ohtani T, Yokoyama N, Nitta K (2009) Invasive cholangiocarcinoma identified in congenital biliary dilatation in a 3-year-old boy. *J Pediatr Surg* 44:2202–2205
12. Gao R, Ke M, Shi J, Zhang Y, Zou J, Diao M, Li L (2023) Establishment and validation of a predictive nomogram for the risk of premalignant lesions in children with choledochal cyst. *Front Pediatr* 11:1108788. <https://doi.org/10.3389/fped.2023.1108788>
13. Sastry AV, Abbadessa B, Wayne MG, Steele JG, Cooperman AM (2015) What is the incidence of biliary carcinoma in choledochal cyst, when do they develop, and how should it affect management? *World J Surg* 39:487–492
14. Mukai M, Kaji T, Masuya R, Yamada K, Sugita K, Moriguchi T (2018) Long-term outcome of surgery for choledochal a single-institution study focusing on follow-up and late complications. *Surg Today* 48:835–840
15. Madadi-Sanjani O, Wirth TC, Kuebler JF, Petersen C, Ure BM (2019) Choledochal cyst and malignancy: a plea for lifelong follow-up. *Eur J Pediatr Surg* 29:143–149
16. Shimada K, Yanagisawa J, Nakayama F (1991) Increased lysophosphatidylcholine and pancreatic enzyme content in bile of patients with anomalous pancreaticobiliary ductal junction. *Hepatology* 13:438–444
17. Mihalache F, Tantau M, Diaconu B, Acalovchi M (2010) Survival and quality of life of cholangiocarcinoma patients: a prospective study over a 4-year period. *J Gastrointest Liver Dis* 19:285–290

18. Levy M, Lin F, Xu H, Dhall D, Spaulding BO, Wang HL (2010) S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy. *Human Pathol* 41:1210–1219
19. Chen L, Haung K, Himmelfarb EA, Zhai J, Lai JP, Lin F, Wang HL (2015) Diagnostic value of maspin in distinguishing adenocarcinoma from benign biliary epithelium on endoscopic bile duct biopsy. *Human Pathol* 46:1647–1654
20. Koga H, Ochi T, Seo S, Miyake Y, Lane GJ, Yamataka A (2022) Comparison of 2K and 4K imaging systems for choledochal cyst in children. *J Pediatr Surg* 57:235–238
21. Miyano G, Koga H, Shimotakahara A, Takahashi T, Kato Y, Lane GJ, Okazaki T, Yamataka A (2011) Intralaparoscopic endoscopy:

its value during laparoscopic repair of choledochal cyst. *Pediatr Surg Int* 27:462–466

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.